{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:12:02Z","timestamp":1780449122944,"version":"3.54.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":162,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>A number of mutations related to malignant melanoma (MM) have been identified, and of the mutated genes, BRAF has been found to be altered in &amp;gt;\u200950% of cases. Most of these have been BRAF V600E mutations, whereas the incidence of BRAF V600K may vary from 10% to 30%. Little is known about the clinical prognostic correlations of BRAF V600K MMs. We evaluated the clinical and dermoscopic features, incidence, therapy response and outcomes in the medium to long term.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To compare the clinical and dermoscopic characteristics, the response to systemic therapies and the prognosis among MMs with BRAF V600E and BRAF V600K mutations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrieved the data of patients tested in our centre for MM from 2012 to 2015, including clinical features, dermoscopic pictures, clinical history and tumour mutations. Only patients with BRAF V600E and BRAF V600K mutations were included. Any MMs positive for BRAF V600K mutation were collected, and the number of V600K cases and their features were used to extract the same number of patients with BRAF V600E from our database using a matching method. The clinical and dermoscopic presentation, therapy response and disease progression of the two groups were then evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 132 cases of BRAF V600E-mutated MMs were identified, and then randomized with a propensity-score method to match the 10 retrieved cases of BRAF V600K mutation. Both groups had a nodular appearance to the tumours and an advanced disease stage, and no significant differences in dermoscopic features were highlighted. During the follow-up period, four patients with BRAF V600K died of disease-specific causes. Moreover, we found a higher frequency of metastasis, a faster disease progression and more rapid mortality in patients with BRAF V600K.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite the small size of this study, the results show similar clinical and dermoscopic characteristics between V600E and V600K mutations, but compared with BRAF V600E MMs, BRAF V600K MMs seem to be less responsive to therapy and have a worse prognosis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ced.15113","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T12:18:00Z","timestamp":1643199480000},"page":"1131-1136","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3323-9216","authenticated-orcid":false,"given":"Corrado","family":"Zengarini","sequence":"first","affiliation":[{"name":"Division of Dermatology IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy"},{"name":"Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-6112","authenticated-orcid":false,"given":"Martina","family":"Mussi","sequence":"additional","affiliation":[{"name":"Division of Dermatology IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy"},{"name":"Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6595-7776","authenticated-orcid":false,"given":"Giulia","family":"Veronesi","sequence":"additional","affiliation":[{"name":"Division of Dermatology IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy"},{"name":"Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-4861","authenticated-orcid":false,"given":"Aurora","family":"Alessandrini","sequence":"additional","affiliation":[{"name":"Division of Dermatology IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy"},{"name":"Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4282-342X","authenticated-orcid":false,"given":"Martina","family":"Lambertini","sequence":"additional","affiliation":[{"name":"Division of Dermatology IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy"},{"name":"Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-2861","authenticated-orcid":false,"given":"Emi","family":"Dika","sequence":"additional","affiliation":[{"name":"Division of Dermatology IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy"},{"name":"Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine University of Bologna Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM196403122701101","article-title":"Melanocyte-stimulating hormone and adrenocorticotrophic hormone \u2013 their relation to pigmentation","volume":"270","author":"Lerner","year":"1964","journal-title":"N Engl J Med"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bcp.2010.04.029","article-title":"Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail","volume":"80","author":"Inamdar","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.361","article-title":"Differential immunoexpression of BRAF\/V600E, senescence markers, PTEN, and T-type calcium channels in acquired naevi according to their histopathological and dermoscopic classification","volume":"101","author":"Moreno","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/bjc.2013.622","article-title":"Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations","volume":"109","author":"Heinzerling","year":"2013","journal-title":"Br J Cancer"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11912-016-0531-z","article-title":"Influences of BRAF inhibitors on the immune microenvironment and the rationale for combined molecular and immune targeted therapy","volume":"18","author":"Reddy","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1758834011432949","article-title":"The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence","volume":"4","author":"Lemech","year":"2012","journal-title":"Ther Adv Med Oncol"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":"BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site","volume":"24","author":"Bauer","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bjd.13069","article-title":"Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma","volume":"171","author":"Pozzobon","year":"2014","journal-title":"Br J Dermatol"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1111\/jdv.15906","article-title":"Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil","volume":"34","author":"Gouillon","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/jdv.14028","article-title":"Association between dermoscopic and reflectance confocal microscopy features of cutaneous melanoma with BRAF mutational status","volume":"31","author":"Bombonato","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/jid.2014.366","article-title":"Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma","volume":"135","author":"Siroy","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1245\/s10434-012-2457-5","article-title":"Prognostic value of BRAF(V600) mutations in melanoma patients after resection of metastatic lymph nodes","volume":"19","author":"Moreau","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/CMR.0000000000000388","article-title":"Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma","volume":"27","author":"Li","year":"2017","journal-title":"Melanoma Res"},{"key":"2023022412434662300_","first-page":"69","article-title":"Reducing bias in cancer research: application of propensity score matching","volume":"29","author":"Reeve","year":"2008","journal-title":"Health Care Financ Rev"},{"key":"2023022412434662300_","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/1078-0432.CCR-18-1680","article-title":"Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma","volume":"25","author":"Pires da Silva","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ced.15113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ced.15113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/47\/6\/1131\/49328371\/ced1131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/47\/6\/1131\/49328371\/ced1131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T08:41:30Z","timestamp":1700124090000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/47\/6\/1131\/6693057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1111\/ced.15113","relation":{},"ISSN":["1365-2230","0307-6938"],"issn-type":[{"value":"1365-2230","type":"electronic"},{"value":"0307-6938","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"2021-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}